Stay updated with breaking news from Objective Response Rate. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CRISPR Therapeutics shares traded as high as $200 18 months ago, but today the share price is $62, and market cap valuation $4.75bn. Read about CRSP here.
Further expansion of patent portfolio supports of the Company's extensive Ampligen research program across multiple types of cancers and viral diseases, including COVID-19 in the NetherlandsOCALA, Fla.
– Zandelisib Demonstrated 70.3% Objective Response Rate and 35.2% Complete Response Rate –– 87.5% of Responses Achieved in First Two Cycles of Therapy, 75% of CRs in First Four Cycles –– 9.9% of Patients Discontinued Therapy Due to a Drug Related Adverse Event –– 83% Reported Grade 3 Adverse Events of Special Intere...
NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical...
G1 Therapeutics Provides First Quarter 2022 Financial Results and Operational Highlights - read this article along with other careers information, tips and advice on BioSpace